On January 6, 2022 Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, reported the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022 (Press release, Galectin Therapeutics, JAN 6, 2022, View Source/news-releases/news-release-details/galectin-therapeutics-present-hc-wainwright-bioconnect" target="_blank" title="View Source/news-releases/news-release-details/galectin-therapeutics-present-hc-wainwright-bioconnect" rel="nofollow">View Source [SID1234598360]). Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the Company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A webcast of this presentation will be available on the "Investor Relations" section under "Events and Presentations" of the Company’s website, View Source, at 7:00 a.m. ET on January 10, 2022. A replay will be accessible on Galectin’s website for 90 days following the event.